Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.36 |
| ▸ | CES1 | P23141 | 3/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL447524 | 1.00 | CES2 (0.36) | CES2CES1EPHX1GGPS1 | |
| SCHEMBL905454 | 1.00 | CES2 (0.36) | CES2CES1EPHX1GGPS1 | |
| SCHEMBL3402212 | 1.00 | CES2 (0.36) | CES2CES1EPHX1GGPS1 | |
| SCHEMBL905462 | 1.00 | CES2 (0.36) | CES2CES1EPHX1GGPS1 | |
| SCHEMBL3185089 | 1.00 | CES2 (0.36) | CES2CES1EPHX1GGPS1 | |
| SCHEMBL1017329 | 0.98 | CES2 (0.33) | CES2CES1EPHX1 | |
| SCHEMBL6243940 | 0.93 | MEN1 (0.33) | CES2CES1EPHX1 | |
| SCHEMBL8490429 | 0.87 | BBOX1 (0.44) | — | |
| SCHEMBL8495180 | 0.87 | BBOX1 (0.44) | — | |
| SCHEMBL8494318 | 0.87 | BBOX1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1575 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118215507-A | Lyophilized ENPP1 polypeptide formulations and uses thereof | 依诺兹梅制药公司 | 2024-06-18 | — | — | CN | claimed |
| US-11998584-B2 | Conjugate of a tubulysin analog with branched linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2024-06-04 | — | — | US | claimed |
| EP-3782550-B1 | ZWITTERION SURFACE MODIFICATIONS FOR CONTINUOUS SENSORS | DEXCOM INC (US) | 2023-12-27 | — | — | EP | claimed |
| EP-3397398-B1 | BIOINTERFACE LAYER FOR ANALYTE SENSORS | DEXCOM INC (US) | 2023-11-08 | — | — | EP | claimed |
| EP-3397162-B1 | MEMBRANE LAYERS FOR ANALYTE SENSORS | DEXCOM INC (US) | 2023-09-06 | — | — | EP | claimed |
| US-20230165931-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-06-01 | — | — | US | claimed |
| WO-2023078021-A1 | BCMA MONOCLONAL ANTIBODY AND THE ANTIBODY-DRUG CONJUGATE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-11 | — | — | WO | claimed |
| WO-2023078273-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-11 | — | — | WO | claimed |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2023-04-13 | — | — | US | claimed |
| WO-2023049864-A1 | LYOPHILIZED ENPP1 POLYPEPTIDE FORMULATIONS AND USES THEREOF | INOZYME PHARMA, INC. (US) | 2023-03-30 | — | — | WO | claimed |
| WO-2018116198-A1 | IMPROVED METHODS FOR ENHANCING ANTIBODY PRODUCTIVITY IN MAMMALIAN CELL CULTURE AND MINIMIZING AGGREGATION DURING DOWNSTREAM, FORMULATION PROCESSES AND STABLE ANTIBODY FORMULATIONS OBTAINED THEREOF | SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN) | 2018-06-28 | — | — | WO | claimed |
| US-20180000932-A1 | FORMULATION OF AGLYCOSYLATED THERAPEUTIC ANTIBODIES | NOVELMED THERAPEUTICS INC (US) | 2018-01-04 | — | — | US | claimed |
| EP-3240571-A1 | FORMULATION OF AGLYCOSYLATED THERAPEUTIC ANTIBODIES | NovelMed Therapeutics, Inc. (US) | 2017-11-08 | — | — | EP | claimed |
| EP-2585105-B1 | TREATMENT OF SANFILIPPO SYNDROME TYPE B | SHIRE HUMAN GENETIC THERAPIES (US) | 2017-08-09 | — | — | EP | claimed |
| EP-3048899-A2 | ON-COLUMN VIRAL INACTIVATION METHODS | Biogen MA Inc. (US) | 2016-08-03 | — | — | EP | claimed |
| WO-2016109822-A1 | FORMULATION OF AGLYCOSYLATED THERAPEUTIC ANTIBODIES | NOVELMED THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | claimed |
| WO-2015048330-A2 | ON-COLUMN VIRAL INACTIVATION METHODS | BIOGEN IDEC MA INC. (US) | 2015-04-02 | — | — | WO | claimed |
| US-20100151451-A1 | Method for Identifying the Genotype in Position 171 of the Ovine Prion Protein as well as Kits for Implementing said Method | BIO-RAD PASTEUR (FR) | 2010-06-17 | — | — | US | claimed |
| EP-1952153-A2 | METHOD FOR IDENTIFYING THE GENOTYPE IN POSITION 171 OF THE OVINE PRION PROTEIN AS WELL AS KITS FOR IMPLEMENTING SAID METHOD | Bio-Rad Pasteur (FR) | 2008-08-06 | — | — | EP | claimed |
| WO-2007060373-A2 | METHOD FOR IDENTIFYING THE GENOTYPE IN POSITION 171 OF THE SHEEP PRION PROTEIN AS WELL AS KITS FOR IMPLEMENTING SAID METHOD | BIO-RAD PASTEUR (FR) | 2007-05-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165931-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | TEKT1, CD2BP2, CD4 | CES2 4727/4885CES1 3979/4885EPHX1 3794/4885 |
| US-11998584-B2 | Conjugate of a tubulysin analog with branched linkers | TEKT1, TEK, CD2BP2 | CES2 4747/4885CES1 4088/4885EPHX1 3619/4885 |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | CD2BP2, EPCAM, CD74 | CES2 1277/4885CES1 2149/4885EPHX1 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.